Our study provides a clue that the combination of VS-4718 with ABCB1 or ABCG2 substrate-drugs, like doxorubicin or topotecan, as well as SN-38, could be a novel treatment strategy to antagonize resistance in cancer patients. This evidence concerns the gene ABCB1 and cancer.